Reactivation of mutant p53: molecular mechanisms and therapeutic potential - PubMed (original) (raw)
Review
. 2007 Apr 2;26(15):2243-54.
doi: 10.1038/sj.onc.1210295.
Affiliations
- PMID: 17401433
- DOI: 10.1038/sj.onc.1210295
Review
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
G Selivanova et al. Oncogene. 2007.
Abstract
The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53 mutations are missense point mutations that cluster in the DNA-binding core domain. This results in distortion of core domain folding and disruption of DNA binding and transcriptional transactivation of p53 target genes. Structural studies have demonstrated that mutant p53 core domain unfolding is not irreversible. Mutant p53 is expressed at high levels in many tumors. Therefore, mutant p53 is a promising target for novel cancer therapy. Mutant p53 reactivation will restore p53-dependent apoptosis, resulting in efficient removal of tumor cells. A number of strategies for targeting mutant p53 have been designed, including peptides and small molecules that restore the active conformation and DNA binding to mutant p53 and induce p53-dependent suppression of tumor cell growth in vitro and in vivo. This opens possibilities for the clinical application of mutant p53 reactivation in the treatment of cancer.
Similar articles
- Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN, Henckel J, Fersht AR. Bullock AN, et al. Oncogene. 2000 Mar 2;19(10):1245-56. doi: 10.1038/sj.onc.1203434. Oncogene. 2000. PMID: 10713666 - Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Suad O, et al. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. J Mol Biol. 2009. PMID: 18996393 - [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P, Nenutil R, Vojtĕsek B. Müller P, et al. Cas Lek Cesk. 2004;143(5):313-7. Cas Lek Cesk. 2004. PMID: 15305766 Review. Czech. - Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A, Rotter V. Sigal A, et al. Cancer Res. 2000 Dec 15;60(24):6788-93. Cancer Res. 2000. PMID: 11156366 Review. - TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S, Dimant H, Dor-On E, Azriel-Rosenfeld R, Benhar I, Solomon B. Orgad S, et al. J Immunother. 2010 Feb-Mar;33(2):146-54. doi: 10.1097/CJI.0b013e3181be14dc. J Immunother. 2010. PMID: 20139776
Cited by
- Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.
Zhang CZ, Chen GG, Merchant JL, Lai PB. Zhang CZ, et al. Cell Cycle. 2012 Jan 15;11(2):322-34. doi: 10.4161/cc.11.2.18758. Epub 2012 Jan 15. Cell Cycle. 2012. PMID: 22214764 Free PMC article. - Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells.
García-Garrido E, Cordani M, Somoza Á. García-Garrido E, et al. Pharmaceutics. 2021 Dec 3;13(12):2067. doi: 10.3390/pharmaceutics13122067. Pharmaceutics. 2021. PMID: 34959348 Free PMC article. - Reactivation of p53 in cells expressing hepatitis B virus X-protein involves p53 phosphorylation and a reduction of Hdm2.
Wang JH, Yun C, Kim S, Chae S, Lee YI, Kim WH, Lee JH, Kim W, Cho H. Wang JH, et al. Cancer Sci. 2008 May;99(5):888-93. doi: 10.1111/j.1349-7006.2008.00754.x. Epub 2008 Feb 24. Cancer Sci. 2008. PMID: 18294283 Free PMC article. - Disease-modifying therapy for proteinopathies: Can the exception become the rule?
Bitan G. Bitan G. Prog Mol Biol Transl Sci. 2019;168:277-287. doi: 10.1016/bs.pmbts.2019.07.010. Epub 2019 Aug 7. Prog Mol Biol Transl Sci. 2019. PMID: 31699321 Free PMC article. Review. - Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis.
Lee DJ, Schönleben F, Banuchi VE, Qiu W, Close LG, Assaad AM, Su GH. Lee DJ, et al. Cancer Biol Ther. 2010 Oct 1;10(7):689-93. doi: 10.4161/cbt.10.7.12886. Epub 2010 Oct 1. Cancer Biol Ther. 2010. PMID: 20657180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous